(0.20%) 5 142.00 points
(0.17%) 38 506 points
(0.28%) 17 896 points
(-0.30%) $83.60
(1.92%) $1.960
(0.10%) $2 349.50
(0.51%) $27.68
(1.05%) $931.80
(-0.05%) $0.934
(-0.14%) $11.01
(-0.19%) $0.799
(1.29%) $93.06
Live Chart Being Loaded With Signals
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally...
Stats | |
---|---|
本日の出来高 | 4 704.00 |
平均出来高 | 10 001.00 |
時価総額 | 138.41M |
EPS | €0 ( 2024-03-24 ) |
次の収益日 | ( €0 ) 2024-07-11 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -6.19 |
ATR14 | €0 (0.00%) |
Heidelberg Pharma AG 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Heidelberg Pharma AG 財務諸表
Annual | 2023 |
収益: | €9.86M |
総利益: | €5.73M (58.10 %) |
EPS: | €-0.440 |
FY | 2023 |
収益: | €9.86M |
総利益: | €5.73M (58.10 %) |
EPS: | €-0.440 |
FY | 2022 |
収益: | €18.51M |
総利益: | €13.83M (74.73 %) |
EPS: | €-0.530 |
FY | 2021 |
収益: | €1.75M |
総利益: | €-2.96M (-169.29 %) |
EPS: | €-0.0649 |
Financial Reports:
No articles found.
Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。